Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell of proximal tubule | 6 studies | 29% ± 8% | |
hepatocyte | 4 studies | 37% ± 19% |
Insufficient scRNA-seq data for expression of HAO2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 8211.82 | 226 / 226 | 74% | 65.29 | 302 / 406 |
kidney | 100% | 4146.67 | 89 / 89 | 72% | 35.67 | 649 / 901 |
adrenal gland | 100% | 64.33 | 257 / 258 | 7% | 0.36 | 15 / 230 |
spleen | 76% | 20.20 | 184 / 241 | 0% | 0 | 0 / 0 |
breast | 66% | 8.34 | 305 / 459 | 4% | 2.31 | 40 / 1118 |
skin | 64% | 158.93 | 1153 / 1809 | 5% | 0.83 | 24 / 472 |
prostate | 64% | 7.54 | 157 / 245 | 0% | 0.06 | 1 / 502 |
ovary | 64% | 5.09 | 115 / 180 | 0% | 0 | 0 / 430 |
adipose | 62% | 7.18 | 743 / 1204 | 0% | 0 | 0 / 0 |
thymus | 46% | 3.40 | 303 / 653 | 4% | 0.54 | 24 / 605 |
intestine | 42% | 4.45 | 407 / 966 | 1% | 0.19 | 3 / 527 |
uterus | 38% | 2.86 | 65 / 170 | 2% | 0.10 | 7 / 459 |
bladder | 38% | 3.76 | 8 / 21 | 1% | 0.07 | 4 / 504 |
lung | 35% | 2.42 | 203 / 578 | 0% | 0.00 | 1 / 1155 |
blood vessel | 34% | 2.68 | 450 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 28% | 16.22 | 264 / 929 | 0% | 0 | 0 / 0 |
pancreas | 26% | 2.09 | 85 / 328 | 2% | 0.12 | 3 / 178 |
stomach | 25% | 1.64 | 90 / 359 | 2% | 0.11 | 5 / 286 |
esophagus | 23% | 1.59 | 333 / 1445 | 2% | 0.11 | 4 / 183 |
brain | 21% | 1.26 | 548 / 2642 | 0% | 0.00 | 1 / 705 |
heart | 20% | 1.48 | 176 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 10% | 12.55 | 3 / 29 |
muscle | 8% | 0.43 | 68 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.25 | 2 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019395 | Biological process | fatty acid oxidation |
GO_0001561 | Biological process | fatty acid alpha-oxidation |
GO_0005829 | Cellular component | cytosol |
GO_0005782 | Cellular component | peroxisomal matrix |
GO_0010181 | Molecular function | FMN binding |
GO_0003973 | Molecular function | (S)-2-hydroxy-acid oxidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | HAO2 |
Protein name | 2-Hydroxyacid oxidase 2 (HAOX2) (EC 1.1.3.15) ((S)-2-hydroxy-acid oxidase, peroxisomal) (Cell growth-inhibiting gene 16 protein) (Long chain alpha-hydroxy acid oxidase) (Long-chain L-2-hydroxy acid oxidase) Hydroxyacid oxidase 2 |
Synonyms | HAOX2 GIG16 |
Description | FUNCTION: Oxidase that catalyzes the oxidation of medium and long chain hydroxyacids such as 2-hydroxyhexadecanoate and 2-hydroxyoctanoate, to the correspondong 2-oxoacids . Its role in the oxidation of 2-hydroxy fatty acids may contribute to the general pathway of fatty acid alpha-oxidation (Probable). Active in vitro with the artificial electron acceptor 2,6-dichlorophenolindophenol (DCIP), but O2 is believed to be the physiological electron acceptor, leading to the production of H2O2. Is not active on glycolate, glyoxylate, L-lactate and 2-hydroxybutanoate . . |
Accessions | ENST00000325945.4 [Q9NYQ3-1] Q9NYQ3 ENST00000361035.8 [Q9NYQ3-2] Q5QP02 ENST00000457318.5 ENST00000622548.4 [Q9NYQ3-1] |